Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter TNF alpha (Adalimumab Biosimilar) Antikörper

Reaktivität: Human FACS, in vivo Wirt: Maus Monoclonal D2E7 unconjugated Recombinant Antibody
Produktnummer ABIN7200655
  • Target Alle TNF alpha (Adalimumab Biosimilar) Produkte
    TNF alpha (Adalimumab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    Human
    Wirt
    • 2
    • 1
    • 1
    Maus
    Klonalität
    • 4
    Monoklonal
    Konjugat
    • 4
    Dieser TNF alpha (Adalimumab Biosimilar) Antikörper ist unkonjugiert
    Applikation
    • 3
    • 2
    • 2
    • 2
    • 1
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Verwendungszweck
    Adalimumab Biosimilar, TNF alpha Monoclonal Antibody
    Spezifität
    The monoclonal antibody adalimumab biosimilar specifically binds to the human TNF alpha.
    Produktmerkmale
    Recombinant Humanized IgG1 Monoclonal Antibody.
    Aufreinigung
    Protein A affinity column
    Reinheit
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterilität
    0.2 μm filtered
    Endotoxin-Niveau
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The monoclonal antibody adalimumab biosimilar was produced in the adalimumab biosimilar CHO stable cell line.
    Klon
    D2E7
    Isotyp
    IgG1 kappa
  • Applikationshinweise
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by adalimumab.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Konservierungsmittel
    Without preservative
    Handhabung
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Haltbarkeit
    12 months
  • Target
    TNF alpha (Adalimumab Biosimilar)
    Abstract
    TNF alpha (Adalimumab Biosimilar) Produkte
    Synonyme
    DIF antikoerper, TNF-alpha antikoerper, TNFA antikoerper, TNFSF2 antikoerper, tumor necrosis factor antikoerper, TNF antikoerper
    Substanzklasse
    Biosimilar
    Hintergrund
    Adalimumab, the first fully human monoclonal antibody drug approved by FDA, binds to TNFα, inactivates TNF receptors, and downregulates the inflammatory reactions associated with a variety of autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.

    Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of immune cells. As a member of a group of cytokines that stimulate the acute phase reaction, TNF is involved in systemic inflammation and able to induce fever, apoptotic cell death, cachexia, inflammation, and to inhibit tumorigenesis and viral replication and respond to sepsis via IL1 & IL6 producing cells. Dysregulation of TNF expression could have serious impact in a variety of human diseases including Alzheimer's disease, cancer, major depression and inflammatory bowel disease.
Sie sind hier:
Kundenservice